SCHEMBL4297304

SCHEMBL4297304

Cc1nccn2c(-c3ccc4nnc(C(C)C)n4n3)c(-c3ccc(F)cc3F)nc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 18/20 0.68
MAP4K4 O95819 17/20 0.68
MAPK9 P45984 15/20 0.68
PRKD3 O94806 15/20 0.68
PRKD2 Q9BZL6 13/20 0.68
MINK1 Q8N4C8 13/20 0.68
EGFR P00533 6/20 0.59
CSNK1A1 P48729 10/20 0.51
MAP4K5 Q9Y4K4 5/20 0.51
MAPK14 Q16539 4/20 0.51
MAPK8 P45983 9/20 0.49
TAOK1 Q7L7X3 8/20 0.49
GSK3B P49841 8/20 0.49
CSNK1G3 Q9Y6M4 7/20 0.49
CSNK1G2 P78368 6/20 0.49
LIMK1 P53667 4/20 0.49
CLK4 Q9HAZ1 3/20 0.49
PRKCG P05129 1/20 0.49
EPHA2 P29317 1/20 0.49
PRKX P51817 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4299237 0.81 MAP4K4 (0.71) CSNK1DMAP4K4MAPK9PRKD3PRKD2
SCHEMBL4300444 0.81 MAP4K4 (1.00) CSNK1DMAP4K4MAPK9PRKD3PRKD2
SCHEMBL4308498 0.80 MAP4K4 (0.70) CSNK1DMAP4K4MAPK9PRKD3PRKD2
SCHEMBL4300766 0.77 MAP4K4 (0.63) CSNK1DMAP4K4MAPK9PRKD3PRKD2
SCHEMBL9056922 0.77 MAP4K4 (0.64) CSNK1DMAP4K4MAPK9PRKD3PRKD2
SCHEMBL4304066 0.75 CSNK1D (1.00) CSNK1DMAP4K4MAPK9PRKD3PRKD2
SCHEMBL4293934 0.75 MAP4K4 (0.55) CSNK1DMAP4K4MAPK9PRKD3PRKD2
SCHEMBL4300842 0.74 MAP4K4 (0.64) CSNK1DMAP4K4MAPK9PRKD3PRKD2
SCHEMBL4303988 0.74 CSNK1D (0.95) CSNK1DMAP4K4MAPK9PRKD3PRKD2
SCHEMBL4303973 0.73 MAP4K4 (0.58) CSNK1DMAP4K4MAPK9PRKD3PRKD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188083-B2 Triazolopyridazines ABBOTT LABORATORIES (US) 2012-05-29 US disclosed
US-20090270402-A1 Novel triazolopyridazines ABBVIE INC. 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270402-A1 Novel triazolopyridazines MAP3K5, MAP3K1, MAP3K2 CSNK1D 173/4885MAP4K4 24/4885MAPK9 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.